세계의 바이오디펜스 시장(2024-2028년)

The biodefense market is forecasted to grow by USD -7161.34 million during 2023-2028, accelerating at a CAGR of -4.96% during the forecast period. The report on the biodefense market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing threat posed by biological agents, rising threat of bioterrorism, and growing public awareness of impact of infectious diseases.

Technavio's biodefense market is segmented as below:

By Type

• Vaccines
• Drugs

By Application

• COVID 19
• Anthrax
• Smallpox
• Botulism
• Others

By Geographical Landscape

• Asia
• North America
• Europe
• Rest of World (ROW)

This study identifies the rising product launches and strategic alliances among market participants as one of the prime reasons driving the biodefense market growth during the next few years. Also, favorable government initiatives and globalization and increased travel requiring better immuity will lead to sizable demand in the market.

The report on the biodefense market covers the following areas:

• Biodefense market sizing
• Biodefense market forecast
• Biodefense market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading biodefense market vendors that include Alnylam Pharmaceuticals Inc., Appili Therapeutics Inc., AstraZeneca PLC, Bavarian Nordic AS, Chimerix Inc., Dynavax Technologies Corp., Elusys Therapeutics Inc., Emergent BioSolutions Inc., GlaxoSmithKline PLC, Merck and Co. Inc., Neogen Corp., Novavax Inc., Porton Biopharma Ltd., Sanofi SA, Serum Institute of India Pvt. Ltd., SIGA Technologies Inc., Soligenix Inc., Tonix Pharmaceuticals Holding Corp., Zoetis Inc., and Johnson and Johnson. Also, the biodefense market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Table of Contents

1 Executive Summary

• 1.1 Market overview

2 Market Landscape

• 2.1 Market ecosystem

3 Market Sizing

• 3.1 Market definition
• 3.2 Market segment analysis
• 3.3 Market size 2023
• 3.4 Market outlook: Forecast for 2023-2028

4 Historic Market Size

• 4.1 Global biodefense market 2018 - 2022
• 4.2 Type Segment Analysis 2018 - 2022
• 4.3 Application Segment Analysis 2018 - 2022
• 4.4 Geography Segment Analysis 2018 - 2022
• 4.5 Country Segment Analysis 2018 - 2022

5 Five Forces Analysis

• 5.1 Five forces summary
• 5.2 Bargaining power of buyers
• 5.3 Bargaining power of suppliers
• 5.4 Threat of new entrants
• 5.5 Threat of substitutes
• 5.6 Threat of rivalry
• 5.7 Market condition

6 Market Segmentation by Type

• 6.1 Market segments
• 6.2 Comparison by Type
• 6.3 Vaccines - Market size and forecast 2023-2028
• 6.4 Drugs - Market size and forecast 2023-2028
• 6.5 Market opportunity by Type

7 Market Segmentation by Application

• 7.1 Market segments
• 7.2 Comparison by Application
• 7.3 COVID 19 - Market size and forecast 2023-2028
• 7.4 Anthrax - Market size and forecast 2023-2028
• 7.5 Smallpox - Market size and forecast 2023-2028
• 7.6 Botulism - Market size and forecast 2023-2028
• 7.7 Others - Market size and forecast 2023-2028
• 7.8 Market opportunity by Application

8 Customer Landscape

• 8.1 Customer landscape overview

9 Geographic Landscape

• 9.1 Geographic segmentation
• 9.2 Geographic comparison
• 9.3 Asia - Market size and forecast 2023-2028
• 9.4 North America - Market size and forecast 2023-2028
• 9.5 Europe - Market size and forecast 2023-2028
• 9.6 Rest of World (ROW) - Market size and forecast 2023-2028
• 9.7 US - Market size and forecast 2023-2028
• 9.8 China - Market size and forecast 2023-2028
• 9.9 India - Market size and forecast 2023-2028
• 9.10 UK - Market size and forecast 2023-2028
• 9.11 Germany - Market size and forecast 2023-2028
• 9.12 Market opportunity By Geographical Landscape

10 Drivers, Challenges, and Trends

• 10.1 Market drivers
• 10.2 Market challenges
• 10.3 Impact of drivers and challenges
• 10.4 Market trends

11 Vendor Landscape

• 11.1 Overview
• 11.2 Vendor landscape
• 11.3 Landscape disruption
• 11.4 Industry risks

12 Vendor Analysis

• 12.1 Vendors covered
• 12.2 Market positioning of vendors
• 12.3 Alnylam Pharmaceuticals Inc.
• 12.4 Appili Therapeutics Inc.
• 12.5 AstraZeneca PLC
• 12.6 Bavarian Nordic AS
• 12.7 Chimerix Inc.
• 12.8 Dynavax Technologies Corp.
• 12.9 Elusys Therapeutics Inc.
• 12.10 Emergent BioSolutions Inc.
• 12.11 GlaxoSmithKline Plc
• 12.12 Johnson and Johnson
• 12.13 Novavax Inc.
• 12.14 Sanofi SA
• 12.15 SIGA Technologies Inc.
• 12.16 Soligenix Inc.
• 12.17 Tonix Pharmaceuticals Holding Corp.

13 Appendix

• 13.1 Scope of the report
• 13.2 Inclusions and exclusions checklist
• 13.3 Currency conversion rates for US$
• 13.4 Research methodology
• 13.5 List of abbreviations